Research programme: targeted cancer therapeutics - Regeneron Pharmaceuticals
Alternative Names: METxMET bispecific antibody - Regeneron Pharmaceuticals; METxMET bispecific antibody drug conjugate - Regeneron TherapeuticsLatest Information Update: 28 Sep 2022
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunotherapies; Maytansinoids
- Mechanism of Action Immunomodulators; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 24 Jun 2020 Pharmacodynamics data from preclinical trial in Solid tumours released by Regeneron Pharmaceuticals